Two additional novel AI-generated targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) have been discovered using the Benevolent Platform and selected for AstraZeneca’s (AZ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback